Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
Other analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Inhibikase Therapeutics in a research note on Thursday. Finally, Chardan Capital restated a “neutral” rating and issued a $1.50 target price on shares of Inhibikase Therapeutics in a report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $4.75.
Inhibikase Therapeutics Price Performance
NASDAQ IKT opened at $1.52 on Friday. Inhibikase Therapeutics has a fifty-two week low of $1.40 and a fifty-two week high of $2.61. The stock has a market cap of $213.21 million, a price-to-earnings ratio of -3.80 and a beta of 0.94. The business has a fifty day moving average of $1.90 and a 200-day moving average of $1.93.
Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. As a group, analysts anticipate that Inhibikase Therapeutics will post -0.41 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IKT. Kalehua Capital Management LLC grew its position in Inhibikase Therapeutics by 118.4% during the first quarter. Kalehua Capital Management LLC now owns 3,821,890 shares of the company’s stock valued at $6,421,000 after acquiring an additional 2,071,890 shares during the period. SummitTX Capital L.P. purchased a new position in shares of Inhibikase Therapeutics in the 1st quarter worth about $2,561,000. Ally Bridge Group NY LLC purchased a new position in shares of Inhibikase Therapeutics in the 1st quarter worth about $2,226,000. Seven Fleet Capital Management LP raised its holdings in shares of Inhibikase Therapeutics by 6.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 346,900 shares of the company’s stock worth $704,000 after purchasing an additional 21,300 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Inhibikase Therapeutics by 595.3% in the 1st quarter. Bank of America Corp DE now owns 322,704 shares of the company’s stock valued at $542,000 after purchasing an additional 276,293 shares in the last quarter. Institutional investors and hedge funds own 3.81% of the company’s stock.
Inhibikase Therapeutics Company Profile
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.
See Also
- Five stocks we like better than Inhibikase Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
